YEVGENIY KHARITON to Stroke Volume
This is a "connection" page, showing publications YEVGENIY KHARITON has written about Stroke Volume.
Connection Strength
2.006
-
Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in?Heart?Failure With Reduced Ejection?Fraction. JACC Heart Fail. 2019 11; 7(11):933-941.
Score: 0.571
-
Health Status Benefits of Successful?Chronic Total Occlusion Revascularization Across the Spectrum?of?Left Ventricular Function: Insights From the OPEN-CTO Registry. JACC Cardiovasc Interv. 2018 11 26; 11(22):2276-2283.
Score: 0.540
-
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021 11; 27(11):1954-1960.
Score: 0.165
-
Heterogeneity of health status treatment response with sacubitril/valsartan: insights from the CHAMP-HF registry. ESC Heart Fail. 2021 02; 8(1):710-713.
Score: 0.155
-
Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial. Circulation. 2019 10 29; 140(18):1463-1476.
Score: 0.143
-
Target Doses of Heart Failure Medical?Therapy and Blood Pressure: Insights From the CHAMP-HF Registry. JACC Heart Fail. 2019 04; 7(4):350-358.
Score: 0.137
-
Health Status Variation Across Practices in Outpatients With Heart Failure: Insights From the CHAMP-HF (Change the Management of Patients With Heart Failure) Registry. Circ Cardiovasc Qual Outcomes. 2018 04; 11(4):e004668.
Score: 0.129
-
Association of Serial Kansas City Cardiomyopathy Questionnaire Assessments With Death and Hospitalization in Patients With Heart Failure With Preserved and Reduced Ejection Fraction: A Secondary Analysis of 2 Randomized Clinical Trials. JAMA Cardiol. 2017 12 01; 2(12):1315-1321.
Score: 0.126
-
Association between sacubitril/valsartan initiation and real-world health status trajectories over 18?months in heart failure with reduced ejection fraction. ESC Heart Fail. 2021 08; 8(4):2670-2678.
Score: 0.040